ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1809

Clinical Outcome and Antibody Responses Following the Surge of SARS-CoV-2 Omicron Infection Among Patients with Systemic Autoimmune Diseases
Abstract Number: 1810

Alcohol Consumption Amount, Type of Beverage, and Gender, All Matters to Serum Uric Acid Levels
Abstract Number: 1811

Strong Relationships Between Body Component Changes and Serum Uric Acid Variability
Abstract Number: 1812

Duloxetine and the Risk for Cardiovascular Events in US Veterans with Non-Cancer Pain
Abstract Number: 1813

Assessing Immunogenicity of SARS-CoV-2 Vaccine Neoantigen S1 in Autoimmune Rheumatic Disease Patients: A Study on Cellular and Humoral Responses
Abstract Number: 1814

Silica and Other Exposures from Jobs and Hobbies Are Associated with Myositis Phenotype in a National Myositis Registry
Abstract Number: 1815

The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Abstract Number: 1816

Hyperuricemia – Especially “Metabolic Hyperuricemia” – Is Independently Associated with Higher Risk of Fatty Liver
Abstract Number: 1817

Geographic Variability of Inflammatory Bowel Disease Related Mortality, 1999-2019; CDC WONDER
Abstract Number: 1818

Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S
Abstract Number: 1819

Clinical Indications Associated with New Opioid Use for Pain Management in the United Kingdom Using National Primary Care Data
Abstract Number: 1820

Statewide Burden of Osteoarthritis in United States Between 1990-2019: A Systematic and Comparative Benchmarking Study
Abstract Number: 1821

The “Weekend Effect” and Rheumatological Association in Patients with Diffuse Alveolar Haemorrhage
Abstract Number: 1822

The Food and Drug Administration’s (FDA’s) Safety Surveillance of Baricitinib and Tocilizumab for COVID-19 (Disclaimer: This Abstract Reflects the Views of the Authors and Not Necessarily Those of the US FDA)
Abstract Number: 1823

Higher Body Mass Index and Older Age, Both of Which Are Linked to Immunothrombosis Are Associated with Improved Survival with Baricitinib Therapy in COVID-19 Pneumonia

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].